Behavioral and histological analysis of the PLP-α-synuclein transgenic mice treated with anle138b revealed that this aggregation inhibitor effectively attenuated the progression of the MSA-like pathology (Fellner et al., 2016; Heras-Garvin et al., 2019). The gene discussed is SNCA; the disease is multiple system atrophy.